Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 31, 2022, Nanomix Corporation (the "Company") appointed Tadd S.
Lazarus, M.D. as a director of the Company, effective immediately. Dr. Lazarus
does not have any family relationship with any director, executive officer or
person nominated or chosen by us to become an executive officer. There is no
understanding or arrangement between Dr. Lazarus and any other person pursuant
to which Dr. Lazarus was selected as a director. There are no transactions in
which Dr. Lazarus has an interest requiring disclosure under Item 404(a) of
Regulation S-K.
Dr. Lazarus has led multiple organizations as Chief Medical Officer encompassing
biochemistry, medical diagnostics, and patient services arenas. From 2019 to
present, he is the Chief Medical Officer of Inivata Inc and since June of 2022
he also serves as Chief Medical Officer of Achieve Health Management. From 2017
to 2019 he was Chief Medical Officer of, Clinical Genomics. He served as Chief
Medical Officer and Head of Medical & Scientific Affairs, Reimbursement, and
Public Policy at Qiagen from 2013 through 2016. In 2010, Lazarus was at
Gen-Probe Inc., (now Hologic), as Chief Medical Officer and VP of Clinical
Affairs. Lazarus began his career and served for more than 20 years at Roche
Diagnostics, where he held positions including Director of Medical and
Scientific Affairs and North American Medical Director for the molecular
diagnostics, POC, diabetes, clinical chemistry, and immunology lines of
business. Dr. Lazarus received a Bachelor of Science in Biology & Physiology
from Marlboro College and earned his Medical Degree from Ross University School
of Medicine.
On August 31, 2022, the Company issued a press release announcing the
appointment of Dr. Lazarus. The press release is attached as Exhibit 99.1 to
this report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release, dated August 31, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
-1-
© Edgar Online, source Glimpses